Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

714

Enrollment

INDUSTRY

Sponsor class

Conditions

AMD
nAMD
Wet Age-related Macular Degeneration
wAMD
WetAMD
CNV

Interventions

GENETIC: ABBV-RGX-314 Dose 1
GENETIC: ABBV-RGX-314 Dose 2
BIOLOGICAL: Aflibercept (EYLEA®)

Sponsor

AbbVie

Collaborators

[object Object]